Evidence map›Paper›PMID 34401718›Full record

ArticleKidney medicine

Sepsis-Associated Acute Kidney Disease and Long-term Kidney Outcomes.

Alexander H Flannery, Xilong Li, Natalie L Delozier, Robert D Toto, Orson W Moe, Jerry Yee, Javier A Neyra

Abstract read
In one paragraph

Article in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Diagnosing Sepsis Through Proteomic Insights: Findings from a Prospective ICU Cohort.medRxiv : the preprint server for health sciences · 2025
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexander H FlanneryDepartment of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY.
Xilong LiDepartment of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX.
Natalie L DelozierDepartment of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY.
Robert D TotoDivision of Nephrology, Department of Internal Medicine, Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX.
Orson W MoeDivision of Nephrology, Department of Internal Medicine, Charles and Jane Pak Center for Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX.
Jerry YeeDivision of Nephrology and Hypertension, Henry Ford Hospital, Detroit, MI.
Javier A NeyraDivision of Nephrology, Bone and Mineral Metabolism, Department of Internal Medicine, University of Kentucky College of Medicine, Lexington, KY.

Funding

UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
UAB-UCSD O'Brien Core Center for Acute Kidney Injury ResearchP30DK079337 · NIDDK · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SANDERS, PAUL W. · 2008 to 2022
$18.3M
UT Southwestern O'Brien Kidney Research Core CenterP30DK079328 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MOE, ORSON W · 2007 to 2021
$16.9M
Klotho: Therapeutic Agent for Ischemia Reperfusion Induced Acute Kidney InjuryR01DK092461 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HU, MING-CHANG · 2011 to 2021
$3.7M
Blood and Urine Biomarkers for Predicting Long-Term Adverse Kidney and Cardiovascular Outcomes after Cardiac SurgeryR01HL148448 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI FOX, AMANDA A · 2019 to 2023
$3.7M
Klotho and Phosphate in Chronic Kidney Disease: Pathogenesis and TherapeuticsR01DK091392 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI HU, MING-CHANG, MOE, ORSON W · 2011 to 2021
$3.2M
Chronic Kidney Disease Precision Medicine ProjectUH3DK114870 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL, VAZQUEZ, MIGUEL A · 2019 to 2021
$900k
Chronic Kidney Disease Precision Medicine ProjectUG3DK114870 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL, VAZQUEZ, MIGUEL A · 2017 to 2018
$747k
Association of baseline and time-varying serum magnesium levels with cardiovascular disease events in SPRINT participants with and without chronic kidney diseaseR21HL145424 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2019 to 2020
$257k
Artificial Intelligence to Predict Outcomes in Patients with Acute Kidney Injury on Continuous Renal Replacement TherapyR56DK126930 · NIDDK · UNIVERSITY OF KENTUCKY · PI NADKARNI, GIRISH NITIN, NEYRA, JAVIER A. · 2020 to 2020
$100k
NCATS NIH HHS UL1 TR001105NHLBI NIH HHS R01 HL148448NHLBI NIH HHS R21 HL145424NIDDK NIH HHS P30 DK079328NIDDK NIH HHS P30 DK079337NIDDK NIH HHS R01 DK091392NIDDK NIH HHS R01 DK092461NIDDK NIH HHS R56 DK126930NIDDK NIH HHS UG3 DK114870NIDDK NIH HHS UH3 DK114870
6 · The paper itself

Abstract

RATIONALE &

objectiveSepsis-associated acute kidney injury often leads to acute kidney disease (AKD), predisposing patients to long-term complications such as chronic kidney disease (CKD), kidney failure with replacement therapy (KFRT), or mortality. Risk stratification of patients with AKD represents an opportunity to assist with prognostication of long-term kidney complications. STUDY

designSingle-center retrospective cohort. SETTING &

participants6,290 critically ill patients admitted to the intensive care unit with severe sepsis or septic shock. Patients were separated into cohorts based on incident acute kidney injury or not, and survivors identified who were alive and free of KFRT up to 90 days. PREDICTORS: AKD stage (0A, 0C, or ≥1) using the last serum creatinine concentration available by discharge or up to 90 days postdischarge. OUTCOME: Time to development of incident CKD, progression of CKD, KFRT, or death. ANALYTICAL APPROACH: Multivariable Cox proportional hazards models.

resultsPatients surviving kidney injury associated with sepsis often fail to return to baseline kidney function by discharge: 577/1,231 (46.9%) with stage 0C or 1 or greater AKD. AKD stage was significantly associated with the composite primary outcome. Stages 0C AKD and 1 or greater AKD were significantly and progressively associated with the primary outcome when compared with stage 0A AKD (adjusted HR [aHR], 1.74; 95% CI, 1.32-2.29, and aHR, 3.25; 95% CI, 2.52-4.20, respectively). Additionally, stage 1 or greater AKD conferred higher risk above stage 0C AKD (aHR, 1.87; 95% CI, 1.44-2.43). CKD incidence or progression and KFRT, more so than mortality, occurred with greater frequency in higher stages of AKD. LIMITATIONS: Retrospective design, single center, exclusion of patients with KFRT within 90 days of discharge, potential ascertainment bias, and inability to subclassify above AKD stage 1.

conclusionsRisk stratification using recommended AKD stages at hospital discharge or shortly thereafter associates with the development of long-term kidney outcomes following sepsis-associated acute kidney injury.

Indexed as

Acute kidney diseaseacute kidney injurychronic kidney diseaseend-stage renal diseaselong-term outcomessepsis

Identifiers

PMID34401718
PMCPMC8350838

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.